spacer
home > pmps > spring 2017 > partial to particles
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Partial to Particles

Dry powder inhalers (DPIs) are almost exclusively passive devices, relying on the energy supplied by the inhaling patient for dose dispersion. Consequently, their designs are crucial in determining the extent to which this limited energy supply aerosolises the formulation to a respirable particle size. With growing focus on particles towards the finer end of the size distribution, achieving consistent and effective dispersion with any given inhalation profile is becoming increasingly important.

The incorporation of a breath-actuated mechanism (BAM) has been shown to enhance the dispersion performance of DPIs. It works by inhibiting the release of the dose until the pressure drop across the device reaches a certain value, thereby promoting highly energetic dispersion and efficient delivery.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr David Lewis is Head of Laboratory at Chiesi’s Research Centre in Chippenham, UK, which he established in July 2009. He holds a BSc in Physics as well as an MSc and PhD in Aerosol Science from the University of Essex, UK. David has authored over 130 research publications within the fields of pharmaceutics, analytical chemistry and aerosol science, and is co-inventor of 30 patents relating to pressurised MDI formulations and devices.

After graduating from the University of Southampton, UK, Alan Tweedie worked for a year as a Quality Control Chemist at a UK biotechnology company. He then moved to Bristol, where he joined Vectura, a pharma firm specialising in inhalation therapy. As part of an early-stage feasibility team, Alan was involved in the manufacture and analysis of dry powder formulations, discovering a particular interest in the interactions that exist between the device and formulation. In 2011, he started working for Chiesi at the Chippenham Research Centre.

Francesca Mason graduated from the University of Bradford, UK, in 2010 with a degree in Chemistry, Pharmaceuticals and Forensic Science. She joined Chiesi in 2011 at the Chippenham Research Centre and has now been a Scientist for more than five years. Francesca has predominately worked within the atomisation team involved in creating novel and innovative formulation and technology platforms for inhaled drug delivery.
spacer
Dr David Lewis
spacer
spacer
spacer
Alan Tweedle
spacer
spacer
spacer
Francesca Mason
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Wickham Laboratories will be on Stand 8 at the 24th Annual Pharmig Conference in the Nottingham Belfry Hotel, November 16th & 17th


More info >>

White Papers

Detecting Integrity Breaches in a range of Pharmaceutical Blister Package Types using Sepha VisionScan

Sepha Limited

Demonstrating the integrity of pharmaceutical blister packs is critically important, as any defects can affect the shelf life and efficacy of the contents. Compared to bulk packaging, blister packs offer improved product integrity, tamper evidence and reduce the likelihood of misuse. Packs can be composed of either a thermoformed polymer or cold formed aluminium tray, with a number of individual pockets to hold the product. After the tablets or capsules are placed in the pockets, the packs are heat sealed with a paper or foil laminate sheet. These various stages can be completed separately or integrated into a single form, fill and seal process. There is a risk of microbial containment or degradation of the contents if any defects are present in the packaging. Such defects can take the form of rips or pinholes in the tray, or lid materials, faulty seals and channel leaks between pockets.
More info >>

 
Industry Events

BIO-Europe® 2017

6-8 November 2017, Messedamm 26 14055 Berlin Germany

The 23rd annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 3,800 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe's world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement